Upstream Bio's stock slides on Phase 2 severe asthma data for verekitug
Upstream Bio股价因verekitug治疗重度哮喘的2期数据下滑

Upstream Bio on Wednesday said its TSLP-targeting drug met its goal in a mid-stage trial in severe asthma, which is a step forward in its bid to challenge Dupixent and Tezspire down the line.
Upstream Bio周三表示，其靶向TSLP的药物在一项针对重度哮喘的中期试验中达到了研究目标，这为其今后挑战都必妥（Dupixent）和Tezspire迈出了关键一步。